Sunesis Pharmaceuticals, Inc. (SNSS) - Financial and Strategic SWOT Analysis Review

1
Sunesis Pharmaceuticals, Inc. (SNSS) - Financial
and Strategic SWOT Analysis Review
Company Profiles and Conferences
2
Summary

• Sunesis Pharmaceuticals, Inc. (SNSS) - Financial
  and Strategic SWOT Analysis Review provides you
  an in-depth strategic SWOT analysis of the
  companys businesses and operations. The profile
  has been compiled by GlobalData to bring to you a
  clear and an unbiased view of the companys key
  strengths and weaknesses and the potential
  opportunities and threats. The profile helps you
  formulate strategies that augment your business
  by enabling you to understand your partners,
  customers and competitors better.
• The profile contains critical company information
  including
• Business description A detailed description of
  the companys operations and business divisions.
• Corporate strategy Analysts summarization of
  the companys business strategy.

Mob 919223375060 / 919223767111
3

• SWOT Analysis A detailed analysis of the
  companys strengths, weakness, opportunities and
  threats.
• Company history Progression of key events
  associated with the company.
• Major products and services A list of major
  products, services and brands of the company.
• Key competitors A list of key competitors to
  the company.
• Key employees A list of the key executives of
  the company.
• Executive biographies A brief summary of the
  executives employment history.
• Key operational heads A list of personnel
  heading key departments/functions.
• - Important locations and subsidiaries A list
  and contact details of key locations and
  subsidiaries of the company.

Mob 919223375060 / 919223767111
4

• Highlights
• Sunesis Pharmaceuticals, Inc. (Sunesis), formerly
  Mosaic Pharmaceuticals, Inc., is a
  biopharmaceutical company. It develops and
  markets oncology therapeutics to treat solid and
  hematologic cancers. The company's lead product
  candidate vosaroxin is being developed in Phase
  III clinical trials for the treatment of acute
  myeloid leukemia (AML). It is a first-in-class
  anti-cancer quinolone derivative that has not
  been used previously for the treatment of cancer.
  The drug is also being evaluated in Phase II
  clinical trials for the treatment of
  platinum-resistant ovarian cancer.

Mob 919223375060 / 919223767111
5
Table of Contents

• Section 1 - About the Company
• Sunesis Pharmaceuticals, Inc. - Key Facts
• Sunesis Pharmaceuticals, Inc. - Key Employees
• Section 2 Company Analysis
• Sunesis Pharmaceuticals, Inc. - Business
  Description
• Sunesis Pharmaceuticals, Inc. - SWOT Analysis
• Section 3 Company Financial Ratios
• Financial Ratios - Capital Market Ratios
• Financial Ratios - Annual Ratios

Mob 919223375060 / 919223767111
6
Custom Research

• There are times when you may not find the company
  profile of your choice in our database. If that
  is the case then you must go for customized
  research. Our multifarious capabilities,
  cross-sector expertise and detailed knowledge of
  various markets, put us at a unique position to
  take up Custom Research demands of the
  customers. 
• We provide the specifications of the custom
  research job to a dedicated team comprising of
  researchers, analysts and industry experts, who
  have close experience and understanding of global
  markets, competitive landscapes, various business
  models, market shares, drivers, restraints and
  benchmarks. The Custom Research is highly
  insightful and actionable. 

Mob 919223375060 / 919223767111
7
To know more Sunesis Pharmaceuticals, Inc.
(SNSS) - Financial and Strategic SWOT Analysis
Review

z

• Contact Us Mob 919223375060 /
  919223767111Fax [phone] Email id
  info_at_companyprofilesandconferences.com

www.companyprofilesandconferences.com